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Introduction: Experimental studies suggest vitamin D inhibits ovarian carcinogenesis.Yet,
epidemiologic studies of ovarian cancer risk and lifestyle correlates of vitamin D status,
plasma 25-hydroxyvitamin D [25(OH)D], or vitamin D receptor (VDR) variants have been
inconsistent.
Objective:To evaluateVDR genetic associations by high vs. low predicted 25(OH)D, scores
derived from known determinants of plasma 25(OH)D. To assess ovarian cancer asso-
ciations with variants identiﬁed in genome-wide association studies (GWAS) of plasma
25(OH)D.
Methods:WegenotypeduptosevenVDR andeight25(OH)DGWASvariantsintheNurses’
Health Studies (562 cases, 1,553 controls) and New England Case–Control study (1,821
cases, 1,870 controls). We estimated haplotype scores using expectation-maximization-
based algorithms.We used unconditional logistic regression to calculate odds ratios (ORs)
and 95% conﬁdence intervals (CI). We combined study results using DerSimonian and
Laird meta-analysis.
Results: Ovarian cancer risk increased per A allele of rs7975232 (VDR; ORD1.12, 95%
CID1.01–1.25) among all women. When stratiﬁed by predicted 25(OH)D, ovarian cancer
was associated with rs731236 (VDR; per C allele ORD1.31) and rs7975232 (ORD1.38)
among women with high predicted 25(OH)D, but not among women with low levels
(P 0.009). We also observed heterogeneity by predicted 25(OH)D for the ovarian can-
cer association with VDR 30 end haplotypes (P D0.009). Of 25(OH)D-associated GWAS
loci, rs7041 was associated with reduced ovarian cancer risk (perT allele ORD0.92, 95%
CID0.85-0.99), which did not differ by predicted 25(OH)D status.
Conclusion: Our study suggests an inﬂuence of VDR 30 end variants on ovarian cancer
risk may be observed in women with high predicted 25(OH)D, which remained even after
taking multiple comparisons into consideration. Future studies are needed to conﬁrm our
results and explore further the relation between vitamin D exposure, genetic variants, and
ovarian cancer risk.
Keywords: ovarian cancer, vitamin D, polymorphism, haplotype, heterogeneity
INTRODUCTION
Experimental studies suggest that vitamin D and its synthetic
derivativesprotectagainstovariancarcinogenesis,exhibitinganti-
proliferative, and pro-apoptotic effects in ovarian cancer cell
lines (1–4) and antitumor activity in animal models (5, 6). The
vitamin D receptor (VDR), which binds the biologically active
form of vitamin D (1,25-dihydroxyvitamin D [1,25(OH)D]), is
weakly to moderately expressed in normal ovarian cells and more
strongly expressed in many ovarian cancer cells lines and tumor
tissues (2, 7–11). Ecological studies generally support the link
between vitamin D exposure and ovarian cancer risk, observ-
ing higher rates of ovarian cancer incidence and/or mortality
among women living in more northern latitudes (12–16). How-
ever,observationalstudiesusingindividual-leveldataonestimated
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UV radiation exposure, dietary and/or supplemental vitamin D
intake, predicted 25(OH)D scores, and plasma 25(OH)D levels
have been inconsistent (17–30).
Genetic studies may provide another line of evidence for the
vitamin D pathway in ovarian carcinogenesis. To date, nine ovar-
ian cancer genetic susceptibility loci have been identiﬁed by four
genome-wide association studies (GWAS) (31–34). While known
vitamin D pathway genes do not appear to reside at these loci,the
newly established variants explain a relatively small proportion
of excess familial risk (34). Additional common susceptibility loci
are likely to exist, but will require alternate approaches such as
evaluating gene–environment interaction to discover these asso-
ciations. Common polymorphisms in the VDR are suspected to
eitherdirectlyaffectorbeinlinkagedisequilibrium(LD)withvari-
antsthatinﬂuencevitaminDsignaling(35),whichwouldalterthe
biological response to vitamin D at the cellular level. Of the VDR
variants that have been most extensively studied, the rs228570
T allele [a.k.a. FokI restriction fragment length polymorphism
(RFLP)“f”allele] creates a VDR protein that is three amino acids
longer and less transcriptionally active than the protein product
of the C allele (35). A recent meta-analysis including a total of
4,163 cases and 6,801 controls observed a signiﬁcant 9% increase
in ovarian cancer risk associated with each rs228570 T allele (36).
While statistically signiﬁcant associations with ovarian cancer risk
were not observed in a meta-analysis for four other VDR vari-
ants, total sample sizes were smaller than that for rs228570, thus,
reducing power to detect genetic associations (37). Additionally,
vitamin D status of study participants may modify associations
betweenVDR genetic variants and cancer risk (38–41),which has
not yet been explored for ovarian cancer. Further, risk has not
been assessed in relation to GWAS-identiﬁed variants linked to
lower plasma 25-hydroxyvitamin D [25(OH)D] levels (42–44), a
relatively stable indicator of vitamin D status (45).
Toexplorethesegaps,weassessedwhetherassociationsbetween
variants presumed to lower VDR bioactivity or contribute to
vitamin D insufﬁciency, and ovarian cancer risk differed by pre-
dicted25(OH)Dstatusinaretrospectivecase–controlstudy(New
England Case–Control study, NECC) and two case–control stud-
ies nested within the prospective Nurses’Health Study (NHS) and
NHSII cohorts.
MATERIALS AND METHODS
STUDY POPULATIONS
TheNHSisaprospectivecohortstudyof121,700femaleregistered
nurses from 11 US states who were 30–55years of age in 1976.
NHSII began in 1989 and enrolled 116,430 female US registered
nurses aged 25–42 from 14 US states. In both cohorts, biennial
self-administered questionnaires gathered detailed information
on lifestyle, menstrual and reproductive factors, and medical his-
tory since baseline. Blood samples were collected from a subset of
32,826 NHS participants in 1989–1990 and from 29,611 NHSII
participants from 1996 to 1999. Among women who did not pro-
videabloodsample,buccalcellsampleswerecollectedfrom29,864
NHS women in 2000–2002 and 29,859 NHSII women in 2004–
2006.Eligiblecasesconsistedof womenwithbiospecimensamples
diagnosed with pathologically conﬁrmed epithelial ovarian can-
cer within 4years before sample collection up to June 1st of either
2009(buccalcell)or2011(blood)inNHSIIand2010(buccalcell)
or 2012 (blood) in NHS with no prior cancer diagnosis except
non-melanomaskincancer.Controlswererandomlyselectedfrom
among women who had at least one ovary and were free of can-
cer (except non-melanoma skin cancer) up to and including the
questionnairecycleinwhichthecasewasdiagnosed.Controlswere
matched to cases by cohort, biospecimen type, age (1month),
and menopausal status at diagnosis. For participants with blood
samples, controls were additionally matched to cases on post-
menopausal hormone use (current vs. not current), menopausal
status, month/year, time of day, and fasting status at blood col-
lection. Completion of the self-administered questionnaire and
submission of the biospecimen was considered to imply informed
consent. The NHS and NHSII protocols were approved by the
Institutional Review Board of Brigham and Women’s Hospital,
Boston, MA, USA.
TheNECCStudyisapopulation-basedstudyofovariancancer.
WomenresidingineasternMassachusettsorNewHampshirewere
recruited during three enrollment phases (Phase 1: 1992–1997,
Phase 2: 1998–2002, and Phase 3: 2003–2008), corresponding to
three funding periods, the details of which were reported previ-
ously (46, 47). Brieﬂy, 3957 women (1,080 from Phase 1, 1,267
from Phase 2, and 1,610 from Phase 3) residing in eastern Mass-
achusetts or New Hampshire with a diagnosis of incident ovarian
cancer were identiﬁed from hospital tumor boards and statewide
cancer registries. Of the 3,083 eligible women, 2,203 agreed to
participate. Controls were identiﬁed through a combination of
random digit dialing,town books,and drivers’license lists. Exclu-
sion criteria for controls included the inability to be contacted,
history of bilateral oophorectomy, language barriers, or reloca-
tion outside of the study area. In Phase 1, 420 (72%) of eligible
women identiﬁed by random digit dialing and 102 (51%) of eligi-
blewomenidentiﬁedthroughtownbooksagreedtoparticipate.In
Phase 2 and 3, 4,366 potential controls were identiﬁed and 1,578
out of 2,940 eligible women (54%) agreed to participate. Con-
trols were frequency matched to cases by age and study center. At
enrollment, participants were asked to recall known and putative
ovarian cancer risk factors that occurred 1year prior to diag-
nosis (for case subjects) or enrollment (control subjects). Over
95% of enrolled participants provided a blood specimen. Each
participant provided written informed consent. The Institutional
ReviewBoardsof BrighamandWomen’sHospitalandDartmouth
Medical School, Hanover, NH, USA approved the study protocol.
PREDICTED 25(OH)D SCORES
We used covariate exposures reported closest to the time of blood
collection in NHS and NHSII or at enrollment in NECC to calcu-
late menopause-speciﬁc predicted 25(OH)D scores as previously
described (20, 48). Brieﬂy, multiple linear regression models to
predict 25(OH)D levels within NHS and NHSII were developed
and then validated in an independent sample of women with
measured 25(OH)D levels (48). Based on these initial models,
separate linear regression models were subsequently ﬁt among
2,431 premenopausal and 3,101 postmenopausal women with
measured 25(OH)D levels to create menopause-speciﬁc predictor
scores (20). Predictors of plasma 25(OH)D levels were catego-
rized as follows: race/ethnicity (white, black, Hispanic,Asian, and
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other), body mass index (BMI; <22.0, 22.0–24.9, 25.0–29.9, 30–
34.9, 35C kg/m2), total leisure-time physical activity (<3, 3–8.9,
9–17.9, 18–26.9, 27C METS/week in NHS/NHSII; 0, quartiles
hours/week in NECC),energy-adjusted (49) vitamin D from food
(<100, 100–199, 200–299, 300–399, 400C IU/day), supplemental
vitamin D (0, 1–199, 200–399, 400C IU/day), alcohol intake (0,
0.1–4.9, 5–9.9, 10C g/day), postmenopausal hormone use (never,
past, current, unknown; for postmenopausal women only), and
average annual UV-B ﬂux based on state of residence (hereafter
simply referred to as UV-B ﬂux; <113, 113, >113 R-B units in
NHS/NHSII; all NECC participants reside in states with UV-B
ﬂux<113R-Bunits).Age(years),seasonof blooddraw(Summer,
Fall, Winter, and Spring), and laboratory batch were included in
theregressionmodelstoaccountforknownvariationin25(OH)D
levels. We used the beta values of predictors from the appropriate
score to calculate menopause-speciﬁc predicted 25(OH)D levels
in NHS/NHSII (20). Similarly, we applied these NHS/NHSII-
derived beta values as weights for each signiﬁcant predictor to
generatemenopause-speciﬁcpredicted25(OH)DscoresforNECC
participants.
SINGLE NUCLEOTIDE POLYMORPHISM SELECTION AND GENOTYPING
We selected commonly studied Single nucleotide polymorphism
(SNPs) within the VDR gene that either have known or hypothe-
sizedfunctionaleffectsonVDRactivity,expression,and/orcancer
risk (35). Variants putatively associated with reduced VDR activ-
ity were designated as therisk alleles. The rs228570 T allele creates
a VDR protein that is three amino acids longer and less tran-
scriptionally active than the protein product of the C allele. The
G allele of the VDR promoter polymorphism,rs11568820,within
theCdx2bindingsite,resultsinlowerbindingafﬁnityforthetran-
scription factor. Three SNPs at the 30 end of the VDR: rs1544410,
rs7975232, and rs731236 (corresponding RFLPs: BsmI, ApaI, and
TaqI) reside in an area of strong LD, and form several haplo-
types of which G-C-A (i.e.,baT; 48%) and A-A-C (i.e.,BAt; 40%)
are most common. These haplotypes are in LD with long and
short polyA variable number of tandem repeat (VNTR) alleles
in the 30 untranslated region (UTR) of the gene, respectively,
which may alter VDR mRNA stability or translational activity
(35). We selected another VDR 30 end SNP rs739837 (RFLP BglI)
that had been associated with advanced breast cancer risk (50),
and rs1989969 ( 5132 T/C), a promoter SNP that eliminates a
potential GATA-1 transcription factor binding site (51). Addi-
tionally, we genotyped GWAS-identiﬁed SNPs at loci associated
with plasma 25(OH)D levels [cytochrome P450, family 2, sub-
family R, polypeptide 1 (CYP2R1; rs10741657 and rs2060793);
NAD synthase 1 (NADSYN1)/7-dehydrocholesterol reductase
(DHCR7; rs1790349 and rs3829251); group-speciﬁc component
(GC; rs2282679, rs4588, and rs7041), which is also commonly
known as vitamin D binding protein (VDBP); cytochrome P450,
family24,subfamilyA,polypeptide1(CYP24A1;rs6013897)](42–
44). Three of the GWAS loci also were signiﬁcantly associated
with clinical vitamin D insufﬁciency (<75nmol/L) (42). Vari-
ants associated with lower plasma 25(OH)D were considered risk
alleles.
Existing genotype data on rs11568820, rs1544410, rs2282679,
rs228570, and rs7041 were available for NECC Phase 1 and 2
participants from previous analyses (34, 52), whereas genotype
data for NHS,NHSII,and NECC Phase 3 participants were newly
generated for this project. All 15 VDR and vitamin D insufﬁ-
ciency GWAS SNPs were genotyped in NHS and NHSII samples.
To increase sample size for haplotype analyses, we additionally
genotyped rs1544410, rs4588, rs7041, rs731236, and rs7975232 in
NECC Phase 3 samples. Sample sizes for each SNP analyzed are
reported in Table S1 in Supplementary Material. Genomic DNA
was extracted from buffy coat or buccal cell samples using the
QIAamp (Qiagen, Chatsworth, CA, USA) 96-spin blood proto-
col. DNA from NHS and NHSII participants was whole genome
ampliﬁed with GE Healthcare Genomiphi (GE Healthcare Bio-
Sciences Corp.,Piscataway,NJ,USA). Genotyping was performed
at the Dana Farber/Harvard Cancer Center High-Throughput
Genotyping Core using the 50 nuclease assay (Taqman, Applied
Biosystems, Foster City, CA, USA) on the OpenArray® Real-
Time PCR System (Applied Biosystems; NHS/NHSII samples) on
ampliﬁed DNA or the ABI PRISM® 7900HT Sequence Detection
System on genomic DNA (NECC Phase 3 samples). Laboratory
personnel were blinded to case–control status, and each plate
included replicate samples for quality control, which had 100%
concordance.
25-HYDROXYVITAMIN D PLASMA ASSAY
Existingplasma25(OH)DlevelswereavailableforasubsetofNHS
and NHSII participants (N D570), as described previously (52,
53). Brieﬂy, case–control sets and samples from the same cohort
were assayed together by radioimmunoassay and labeled to mask
case–controlstatus.Theintra-assaycoefﬁcientsofvariation,based
on blinded quality control replicates ranged from 8 to 10%.
STATISTICAL ANALYSIS
We used chi-square tests to assess Hardy–Weinberg equilibrium
(HWE) among white controls within NHS/NHSII and NECC.
Three of 15 SNPs (rs1989969, rs2060793, and rs739837) were out
of HWEamongNHS/NHSIIparticipants(P <0.05)andexcluded
fromanalyses.WeexcludedNHS/NHSIIsamplesthatfailedgeno-
typing of ﬁve or more SNPs (15 cases,41 controls).Among NECC
participants, rs1544410 was out of HWE (P D0.004). Review of
screenshotsfortheseplatesrevealedappropriateclusteringandso
rs1544410 was retained to generate VDR 30 end haplotypes. The
rs1544410 risk allele frequency (RAF) among NECC controls was
similar to the RAF among NHS/NHSII controls and the HapMap
Phase IICIII, Release 28 Caucasian European (CEU) population
(Table S1 in Supplementary Material).
We used unconditional logistic regression models adjusted for
matching factors and race to calculate odds ratios (ORs) and
95% conﬁdence intervals (CIs). For each SNP, gene dosage effects
were modeled by assigning a value of 0, 1, or 2 to a geno-
type trend variable according to a participant’s number of risk
alleles. We estimated frequencies of VDR 30 end and GC hap-
lotypes using expectation–maximization-based algorithms and
imputed subject-speciﬁc expected haplotypes (54, 55) to pro-
vide tests of association for individual haplotypes, assuming
additive inheritance models. VDR 30 end haplotypes with esti-
mated frequencies <5% were grouped. We derived estimated
GC phenotypes based on GC haplotype scores and assigned
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Table 1 |Age and selected age-standardized characteristics of ovarian cancer cases and controls by study populationa.
NHS/NHSII NECC
Case (N D562) Control (N D1,553) Case (N D1,821) Control (N D1,870)
Age (years)b 55.0 (7 .9) 55.0 (7 .9) 52.4 (12.3) 52.3 (12.7)
Ever use of oral contraceptives, % 55 55 53 65
Duration of oral contraceptive use (months)c 49.3 (42.8) 54.4 (48.3) 56.0 (56.6) 66.6 (59.6)
Tubal ligation, % 13 21 13 20
Body mass index (kg/m2) 25.9 (5.9) 25.2 (4.7) 26.5 (6.3) 26.0 (5.6)
Total activity (hours/week) 3.5 (3.6) 3.4 (3.8) 3.1 (4.9) 3.3 (4.4)
Total vitamin D intake (IU/day) 382 (261) 381 (272) 412 (299) 417 (290)
Alcohol intake (grams/day) 5.9 (9.7) 6.3 (10.8) 6.8 (11.8) 6.7 (10.8)
aValues are means (SD) or percentages and are standardized to the age distribution of the study population.
bValue is not age-adjusted.
cAmong women who ever used oral contraceptives.
25(OH)D binding afﬁnity constants based on published esti-
mates [Table 1 in Ref. (56)] to a trend variable. Risk allele counts
from the four independent plasma 25(OH)D GWAS loci (rs4588,
rs10741567, rs3829251, and rs6013897) were summed to gen-
erate a genetic risk score (GRS) of vitamin D insufﬁciency in
NHS/NHSII. Unconditional logistic regression models estimated
risk of ovarian cancer associated with the GRS. Linear regression
models adjusted for age, cohort, race, and season of blood draw
were used to estimate SNP and GRS associations with plasma
25(OH)D levels. Wald tests were used to calculate P values for
trend.
Predicted 25(OH)D scores were dichotomized at the median
valuesof menopause-speciﬁccontroldistributionsinNHS/NHSII
and NECC. Women missing predicted 25(OH)D values were
excluded from stratiﬁed analyses and tests for interaction. Within
each study, statistical tests for interaction by predicted 25(OH)D
were performed by the Wald test using cross-product terms. Der-
Simonian and Laird random effects meta-analysis (57) was used
to combine results from NHS/NHSII and NECC. Heterogeneity
by study and by predicted 25(OH)D strata was calculated using
the Q statistic. To calculate a global P value for statistical interac-
tion of VDR 30 end haplotypes by predicted 25(OH)D status, we
pooled individual-level NHS/NHSII and NECC data,additionally
adjusted for study and predicted 25(OH)D scores, and compared
models with interaction terms to a model without interaction
terms using the likelihood ratio test.
P values were based on two-sided tests and considered statisti-
callysigniﬁcantatP <0.05.AllanalyseswereconductedusingSAS
version9.3(SASInstituteInc.,Cary,NC,USA).Powercalculations
were performed using QUANTO (58).
RESULTS
A total of 2,383 (562 NHS/NHSII and 1,821 NECC) cases and
3,423 (1,553 NHS/NHSII and 1,870 NECC) controls were avail-
able for this analysis. Women ranged in age from 34 to 72years
in NHS/NHSII and from 18 to 79years in NECC at the time
of blood collection. As expected based on the matched designs,
cases, and controls were of similar age within each study. On
average, NHS/NHSII participants were slightly older than NECC
participants at the time of blood collection. Within each study,
cases had shorter mean duration of oral contraceptive use and
were less likely to have had a tubal ligation than controls. BMI,
total leisure-time physical activity, total vitamin D intake (food
and supplemental sources), and alcohol consumption were simi-
lar between case and control groups. Total vitamin D intake was
higher in NECC than in NHS/NHSII (Table 1).
Risk allele frequencies observed in our control groups were
comparable to those in the CEU HapMap population (Table
S1 in Supplementary Material). Genotyping success rates were
95% for all SNPs except rs7975232 in NHS/NHSII (93%) and
rs2228570 in NECC (94%). Given high LD between rs1790349
and rs3829251 (r2 D0.79) at the NADSYN1/DHCR7 locus and
between rs2282679 and rs4588 (r2 D0.95) at the GC locus
among NHS/NHSII participants, we selected the SNP with
the higher genotyping success rate for analysis (rs3829251 and
rs4588). We did not observe signiﬁcant heterogeneity in esti-
mates between NHS/NHSII and NECC in the main effect meta-
analysis of SNPs. Of the VDR SNPs assessed, we observed
a signiﬁcant 12% increased risk of ovarian cancer associated
with each rs7975232 A allele (Table 2). A marginal association
between rs2228570 and ovarian cancer risk was also observed
(per T allele ORD1.09, 95% CID1.00–1.19; Ptrend D0.06). The
GWAS-identiﬁed rs7041 T allele was signiﬁcantly associated
with reduced ovarian cancer risk (per allele ORD0.92, 95%
CID0.85–0.99; Ptrend D0.03). We conﬁrmed that the rs7041 T
allele and the vitamin D insufﬁciency GRS were associated with
reduced 25(OH)D levels (Ptrend of 0.005 and <0.0001, respec-
tively) among the subset of NHS/NHSII participants with exist-
ing 25(OH)D measurements (N D570). The vitamin D insufﬁ-
ciency GRS was not associated with ovarian cancer risk (data not
shown).
We took advantage of the strong LD at the 30 end of the VDR
gene (35) to generate haplotype scores that may better capture
the effect of an unknown functional variant. Three SNPs at the
VDR 30 end (rs1544410–rs7975232–rs731236) formed three com-
mon haplotypes and ﬁve haplotypes with frequencies <5% that
weregroupedintoa“rare”haplotypevariable.Ovariancancerrisk
was not associated with the VDR 30 end haplotypes compared
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Table 2 |Association of ovarian cancer withVDR and 25(OH)D GWAS-identiﬁed SNPs in the Nurses’ Health Studies, and the New England
Case–Control study.
SNP Risk
allele
Other
allele
NHS/NHSII NECC Meta-analysis
Per allele OR
(95% CI)a
Ptrend Per allele OR
(95% CI)a
Ptrend Per allele OR
(95% CI)b
Ptrend Phet
c
VITAMIN D RECEPTOR POLYMORPHISMS
rs11568820 G A 1.05 (0.88–1.24) 0.61 0.90 (0.78–1.04) 0.14 0.96 (0.83–1.12) 0.60 0.19
rs1544410 A G 1.09 (0.95–1.25) 0.24 0.98 (0.89–1.08) 0.67 1.02 (0.92–1.12) 0.72 0.23
rs2228570 T C 1.09 (0.95–1.25) 0.24 1.09 (0.97–1.23) 0.14 1.09 (1.00–1.19) 0.06 0.95
rs731236 C T 1.12 (0.97–1.29) 0.13 1.02 (0.87–1.20) 0.81 1.07 (0.96–1.20) 0.20 0.42
rs7975232 A C 1.17 (1.02–1.36) 0.03 1.07 (0.92–1.25) 0.40 1.12 (1.01–1.25) 0.03 0.40
25(OH)D GWAS LOCI
rs4588d T G 0.99 (0.85–1.15) 0.86 0.95 (0.85–1.05) 0.30 0.96 (0.88–1.05) 0.34 0.65
rs7041 T G 0.95 (0.83–1.10) 0.51 0.90 (0.82–0.99) 0.03 0.92 (0.85–0.99) 0.03 0.51
rs10741657d G A 0.96 (0.84–1.11) 0.59 1.14 (1.01–1.30) 0.04 1.05 (0.89–1.24) 0.56 0.08
rs3829251 A G 0.86 (0.71–1.04) 0.13 – – – – –
rs6013897 A T 0.92 (0.77–1.09) 0.32 – – – – –
aOdds ratios (OR) and 95% conﬁdence intervals (CI) estimated using unconditional logistic regression models adjusted for matching factors and race.
bDerSimonian–Laird estimators for random effects models were used to combine results from the pooled Nurses’ Health Studies, and the New England Case–Control
study datasets.
cP-value for heterogeneity in estimates between studies.
drs2282679wassubstitutedforrs4588(r
2 D0.95)andrs2060793wassubstitutedforrs10741657(r
2 D0.88)inasubsetofNewEnglandCase–Controlstudyparticipants
(950 cases and 1,052 controls) that were genotyped on the iCOGS array (34).
to the most common haplotype (G-C-T) in the meta-analysis of
NHS/NHSII and NECC (Table 3).
GC SNPs rs7041 and rs4588 create amino acid substitutions at
positions416and420,respectively,resultinginthreemajorVDBP
isoforms (GC2, GC1s, and GC1f) that vary in binding afﬁnity for
vitamin D analytes (56). We conﬁrmed that allelic combinations
(“GC phenotypes”;see Table3 footnote) estimated to have higher
VDBP binding afﬁnity were positively associated with plasma
25(OH)D levels in NHS/NHSII (Ptrend D0.003). Estimated GC
phenotypes were not associated with ovarian cancer risk in
NHS/NHSII,NECC,or the meta-analysis (Ptrend 0.31; Table3).
Evidence of effect modiﬁcation by vitamin D exposure has
been observed in prior studies of other cancers. Stronger genetic
associations with prostate cancer risk were observed for VDR
variants among men with vitamin D insufﬁciency or low sun
exposure (38–40). In contrast, the BsmI B allele was somewhat
more strongly associated with melanoma risk among participants
with higher sun exposure (41). Therefore, we explored the rela-
tion between ovarian cancer and individual SNPs, VDR 30 end
haplotypes,and estimated GC phenotypes by predicted 25(OH)D
strata. Among women with high (above the median) predicted
25(OH)D levels, we observed signiﬁcant increased risk of ovar-
ian cancer associated with VDR variants rs731236 (per allele C
ORD1.31, 95% CID1.11–1.55; Ptrend D0.002) and rs7975232
(per A allele ORD1.38, 95% CID1.17–1.62; Ptrend D0.0002;
Table4). These SNPs were not associated with ovarian cancer risk
among women with low predicted 25(OH)D levels (Pheterogeneity
of 0.009 and 0.006, respectively). Similarly, heterogeneity in ovar-
ian cancer risk by predicted 25(OH)D was observed for the VDR
30 end haplotypes (P D0.009; Table 5). For each A-A-C or G-A-
T haplotype possessed by women with high predicted 25(OH)D
levels, risk of ovarian cancer signiﬁcantly increased ~40%. These
associations were not observed among women with low pre-
dicted 25(OH)D. To determine whether a particular component
of the predicted 25(OH)D score accounted for the heterogene-
ity, we tested effect modiﬁcation of ovarian cancer associations
with rs731236, rs7975232, and VDR 30 end haplotypes by BMI
(<25 vs. 25C kg/m2), total vitamin D intake (below vs. above
median), total leisure-time physical activity (below vs. above
median), menopausal status and HT use (premenopausal, post-
menopausal/never HT use, postmenopausal/past HT use, and
postmenopausal/current HT use), and alcohol intake (below vs.
above median). Except for heterogeneity in the rs731236 asso-
ciation with ovarian cancer risk by alcohol intake (P D0.03), in
which the increased risk was restricted to women with higher
than the median alcohol intake, we did not observe signiﬁcant
effect modiﬁcation by predicted 25(OH)D score components
(data not shown). The GC rs7041 T allele was associated with
reduced ovarian cancer risk among women with low predicted
25(OH)D (Ptrend D0.03), but the association was not signiﬁ-
cantlydifferentfromthatofwomenwithhighpredicted25(OH)D
(Pheterogeneity D0.39; Table 4). Estimated GC phenotypes were
not associated with ovarian cancer risk regardless of predicted
25(OH)D status (Table 5).
DISCUSSION
In this study, we examined whether the vitamin D status of indi-
viduals modiﬁes genetic associations between VDR variants and
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Table 3 | Risk of ovarian cancer associated withVDR 30 end haplotype
and GC phenotypes in the Nurses’ Health Studies, and the New
England Case–Control study.
NHS/NHSII NECC Meta-analysis
OR (95% CI)a OR (95% CI)a OR (95% CI)b Phet
c
VDR rs1544410–rs7975232–rs731236 HAPLOTYPESd
G-C-T 1.00 (ref) 1.00 (ref) 1.00 (ref)
A-A-C 1.20 (1.01–1.42) 1.02 (0.85–1.22) 1.10 (0.94–1.30) 0.20
G-A-T 1.07 (0.86–1.34) 1.15 (0.89–1.50) 1.10 (0.93–1.31) 0.68
Rare
haplotypes
0.89 (0.65–1.22) 1.30 (0.79–2.13) 1.02 (0.72–1.46) 0.21
GC PHENOTYPESe
GC2-GC2 1.00 (ref) 1.00 (ref) 1.00 (ref)
GC2-GC1s 1.07 (0.73–1.58) 1.00 (0.76–1.31) 1.02 (0.82–1.28) 0.77
GC1s-GC1s 1.08 (0.73–1.58) 1.09 (0.83–1.42) 1.08 (0.87–1.35) 0.97
GC2-GC1f 0.98 (0.60–1.60) 0.73 (0.52–1.03) 0.81 (0.61–1.07) 0.33
GC1s-GC1f 1.13 (0.74–1.71) 0.98 (0.73–1.32) 1.03 (0.81–1.31) 0.60
GC1f-GC1f 0.63 (0.28–1.42) 0.89 (0.56–1.41) 0.82 (0.55–1.22) 0.47
Ptrend
f 0.71 0.32 0.31 0.80
aPerhaplotype(VDR)orperphenotype(GC)oddsratios(OR)and95%conﬁdence
intervals (CI) estimated using unconditional logistic regression models adjusted
for matching factors and race.
bDerSimonian–Laird estimators for random effects models were used to com-
bine results from the Nurses’ Health Studies, and the New England Case–Control
study.
cP-value for heterogeneity in estimates between studies.
dNHS/NHSII sample size: 485 cases, 1,338 controls; NECC sample size: 575
cases, 610 controls.
eGC phenotypes derived from haplotype scores of rs4588 and rs7041 (GC2
haplotype: T-T, GC1s haplotype: G-G, GC1f haplotype: G-T); in subset of NECC
genotyped on the iCOGS array (34) phenotypes were derived from rs2282679
and rs7041 (GC2 haplotype: C-T, GC1s haplotype: A-G, GC1f haplotype: A-T);
NHS/NHSII sample size: 557 cases, 1,523 controls; NECC sample size: 1,587
cases, 1,704 controls.
f25(OH)D binding afﬁnity constants (Ka 10
 10 M) assigned to GC phenotypes
for trend test: GC2-GC2, 3.6; GC2-GC1s, 4.8; GC1s-GC1s, 6.0; GC2-GC1f, 7 .4;
GC1s-GC1f, 8.6; GC1f-GC1f, 11.2 (56).
ovariancancerrisk.Ourresultsprovidesomeevidencethatgenetic
variation at the 30 end of the VDR gene (rs731236, rs7975232, 30
endhaplotypes) mayinﬂuence ovariancancer riskamong women
withhigherpredicted25(OH)Dlevels,butnotamongwomenwith
lower levels. This also is the ﬁrst report to assess whether vitamin
D insufﬁciency GWAS loci are associated with risk. Based on the
anti-proliferative and pro-apoptotic effects of vitamin D on ovar-
ian cancer cell lines (1–4), the rs7041 vitamin D insufﬁciency risk
(T)allelewasunexpectedlyassociatedwithreducedriskofovarian
cancer in our datasets. Outside of theVDR 30end genetic variants,
we did not observe effect modiﬁcation by predicted 25(OH)D
status for the other examined variants.
Overall,we observed that some,but not all,genetic variation at
the30 endof theVDR geneisassociatedwithamodestlyincreased
risk of ovarian cancer. Known vitamin D pathway genes do not
appear to reside at the nine susceptibility loci newly identiﬁed
by ovarian cancer GWAS studies conducted among women from
North America and the UK (31–34). In a US GWAS of ovarian
cancer (n D1,814 cases and 1,867 controls from four studies),
there was no association between the 30 end haplotypes and ovar-
ian cancer risk (unpublished data). However, in our study, we
only observed a positive association for individuals with higher
predicted 25(OH)D status. Since a substantial portion of the US
and UK populations have insufﬁcient vitamin D levels (59, 60),
it may be difﬁcult to observe genetic associations without consid-
ering the vitamin D status of women. The biologic implications
of our results are not entirely clear as we observed heterogeneity
by predicted 25(OH)D status for variants with unknown func-
tional signiﬁcance. VDR 30 end haplotypes are in strong LD with
regulatory elements in the 30 UTR, which may alter VDR mRNA
stability or translational activity. However, reported directions of
associationbetween30 endhaplotypesandVDRexpressionand/or
activityhavebeeninconsistent,whichmaybeduetotissue-speciﬁc
regulation (35). Alternatively, the VDR 30 variants could be in LD
with variants inﬂuencing activity and/or expression of neighbor-
ing genes such as histone deacetylase 7 (HDAC7), which begins
21.6kb downstream of theVDR gene. HDAC7 has been shown to
attenuate 1,25(OH)D-mediated gene transcription in malignant
breast cells (61). Investigating the inﬂuence of VDR 30 end vari-
ants on expression and/or activity of the VDR and neighboring
genes in ovarian cells as well as potential vitamin D activation
of the receptor may provide insight on the relation with ovarian
cancer risk.
An experimental study demonstrated that 1,25(OH)D-
stimulatedVDRactivitydifferedbynaturallyoccurringrs2228570
genotype in peripheral blood mononuclear cells in vitro (62).
The T allele exhibited a dose-dependent effect on the half-
maximal activity of 1,25(OH)D, in which higher concentra-
tions were required to obtain similar inhibition of cell prolif-
eration. However, the polymorphism was not associated with
maximal 1,25(OH)D-mediated growth inhibition. 1,25(OH)D
half-maximal and maximal growth inhibition did not differ by
rs1544410, rs731236, rs7975232 genotypes, or VDR 30 end hap-
lotypes (62). The authors noted that the lack of heterogene-
ity by VDR 30 end haplotypes potentially could have been due
to small sample size (62), which may be true for the indi-
vidual variants as well. Likewise, as common variants often
exhibit weak effects on associated phenotypes, our analysis was
not sufﬁciently powered to detect small differences in ovar-
ian cancer risk by genotype, which may have contributed to
inconsistency between our study and the experimental study.
For example, based on our observed estimates within predicted
25(OH)D strata, our power to detect signiﬁcant relative ORs
of ~1.06 for rs2228570 and ~1.15 for rs1544410 were 10 and
43%, respectively. Further, while the predicted 25(OH)D score
is signiﬁcantly positively correlated with plasma 25(OH)D lev-
els (48), we cannot estimate absolute levels to determine which
subgroup of women are exposed to half-maximal concentra-
tions of 25(OH)D or 1,25(OH)D in order to observe poten-
tial differences by genotype. Lastly, growth inhibition exhib-
ited by 1,25(OH)D on peripheral blood mononuclear cells may
differ from 1,25(OH)D-mediated inhibition of normal and/or
malignant ovarian cells.
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Table 4 |Association of ovarian cancer withVDR and 25(OH)D GWAS-identiﬁed SNPs by predicted 25(OH)D statusa.
SNP Risk
allele
Other
allele
Below median predicted 25(OH)D Above median predicted 25(OH)D Phet
c
Cases/
controls
Per allele OR
(95% CI)b
Ptrend Cases/
controls
Per allele OR
(95% CI)b
Ptrend
VITAMIN D RECEPTOR POLYMORPHISMS
rs11568820 G A 883/1,285 0.94 (0.79–1.13) 0.52 617/1,019 0.90 (0.75–1.09) 0.28 0.72
rs1544410 A G 1,166/1,537 0.97 (0.86–1.08) 0.54 912/1,377 1.12 (0.94–1.33) 0.21 0.16
rs2228570 T C 877/1,286 1.09 (0.91–1.29) 0.35 614/1,009 1.15 (0.99–1.33) 0.07 0.78
rs731236 C T 549/935 0.94 (0.78–1.14) 0.56 472/894 1.31 (1.11–1.55) 0.002 0.009
rs7975232 A C 520/885 0.98 (0.83–1.16) 0.82 481/848 1.38 (1.17–1.62) 0.0002 0.006
25(OH)D GWAS LOCI
rs4588d T G 1,088/1,504 0.97 (0.85–1.09) 0.58 863/1,342 0.93 (0.81–1.06) 0.29 0.74
rs7041 T G 1,087/1,500 0.88 (0.79–0.99) 0.03 857/1,344 0.94 (0.83–1.07) 0.35 0.39
rs10741657d G A 791/1,226 1.06 (0.77–1.47)e 0.71 552/1,965 0.99 (0.85–1.16) 0.90 0.72e
rs3829251f A G 269/692 0.81 (0.60–1.07) 0.14 198/549 0.98 (0.70–1.36) 0.88 0.35
rs6013897f A T 268/694 1.00 (0.78–1.30) 0.98 198/546 0.89 (0.66–1.21) 0.46 0.61
aDerSimonian–Laird estimators for random effects models were used to combine results from the pooled Nurses’ Health Studies, and the New England Case–Control
study datasets.
bOdds ratios (OR) and 95% conﬁdence intervals (CI) estimated using unconditional logistic regression models adjusted for matching factors and race.
cP-value for heterogeneity by predicted 25(OH)D levels.
drs2282679 was substituted for rs4588 (r
2 D0.95) and rs2060793 was substituted for rs10741657 (r
2 D0.88) in a subset of the New England Case–Control study
participants (950 cases and 1,052 controls) genotyped on the iCOGS array (34).
eP<0.05 for test for heterogeneity between the Nurses’ Health Studies, and the New England Case–Control study estimates.
fEstimates only available from the Nurses’ Health Studies.
We hypothesized that validated GWAS variants associated with
lower plasma 25(OH)D levels would result in a lower lifetime
average plasma 25(OH)D levels,increasing risk of ovarian cancer.
IndividualvitaminDinsufﬁciencyvariantsandtheGRSwereasso-
ciated with plasma 25(OH)D in the expected direction among the
subgroup of NHS/NHSII women with measured levels, but were
not associated with ovarian cancer risk. Contrary to expectations,
thers7041Tallelewasassociatedwithreducedovariancancerrisk
(P D0.03). The association could be due to chance considering
the number of statistical tests performed in this study. Another
possibility is that because rs7041, in combination with rs4588,
forms three major VDBP isoforms (GC2, GC1s, and GC1f), and
the rs7041 T allele codes for isoforms with both the lowest (GC2)
and highest (GC1f) binding afﬁnity (56), our study population
may have a higher prevalence of the GC1f compared to the GC2
isoform. However, consistent with prior reports of race-speciﬁc
frequencies (63), the frequency of GC2 (~0.28) was higher than
that of GC1f (~0.15) among our predominantly white study pop-
ulations. The trend variable of estimated GC phenotypes ordered
by increasing binding afﬁnity was associated with higher plasma
25(OH)D, but not ovarian cancer risk in our study. Stratifying by
predicted 25(OH)D did not identify ovarian cancer associations
with individual GWAS variants nor with estimated GC pheno-
types.While we adjusted our analyses for self-reported race,given
racial differences inVDBP isoform frequencies (63),and in risk of
ovarian cancer (64),we cannot exclude the possibility that under-
lying population stratiﬁcation may have confounded our results.
Estimates for all of our analyses were similar when we excluded
women of self-reported non-European ancestry (NHS/NHSII: 29
cases, 74 controls; NECC: 89 cases, 57 controls).
Ourstudyhasseveralstrengthsandlimitations.Whileourstudy
beneﬁtedfromarelativelylargesamplesizeforthemaineffectson
at least a subset of examined SNPs, power to detect heterogeneity
by predicted 25(OH)D status was generally limited. Moreover,the
numerous hypotheses tested relating to SNP main effects, haplo-
types, predicted 25(OH)D strata, and interactions increased the
likelihood of observing false positive results. Even so, increased
ovariancancerriskassociatedwithrs7975232andtheA-A-C30end
haplotype at the VDR locus among women with higher predicted
25(OH)D scores remained signiﬁcant after adjusting the signif-
icance level using a Bonferroni correction (0.05/54D0.0009).
The risk associated with VDR variant rs731236 among this same
subgroup of women also remained signiﬁcant using the less con-
servative False Discovery Rate procedure (65). Our analyses were
aided by the predominantly white study populations, but lacked
ancestry informative markers to control for potential population
stratiﬁcation.Further,ourresultsmaynotbegeneralizabletonon-
whitepopulations,particularlyforVDBPisoforms,thefrequencies
of which are known to vary substantially by race (63). Use of
thequestionnaire-basedpredicted25(OH)Dscoremadeourlarge
study feasible. In general,the heterogeneity observed by predicted
25(OH)D status did not appear to be driven by a single compo-
nentof thescorepredicting25(OH)D,butratherbythescoreinits
entirety.However,weareunabletodirectlytranslatethepredicted
25(OH)D score into absolute 25(OH)D levels. Future follow-up
studies with measured plasma 25(OH)D levels on a larger study
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Table 5 | Risk of ovarian cancer associated withVDR 30 end haplotype
and GC phenotypes by predicted 25(OH)D statusa.
Below median
predicted 25(OH)D
Above median
predicted 25(OH)D
Phet
c
OR (95% CI)b Ptrend OR (95% CI)b Ptrend
VDR rs1544410–rs7975232–rs731236 HAPLOTYPESd
G-C-T 1.00 (ref) 1.00 (ref) 0.009
A-A-C 0.92 (0.73–1.14) 0.44 1.41 (1.16–1.71) 0.0005
G-A-T 1.02 (0.79–1.32) 0.89 1.37 (1.05–1.78) 0.02
Rare
haplotypes
0.87 (0.52–1.45) 0.59 1.34 (0.88–2.04) 0.18
GC PHENOTYPESe
GC2–GC2 1.00 (ref) 1.00 (ref)
GC2–GC1s 1.38 (0.95–2.01) 0.87 (0.35–2.19)f
GC1s–GC1s 1.32 (0.96–1.82) 0.89 (0.63–1.26)
GC2–GC1f 0.99 (0.67–1.47) 0.61 (0.39–0.96)
GC1s–GC1f 1.15 (0.81–1.63) 1.09 (0.56–2.12)
GC1f–GC1f 0.82 (0.38–1.76) 0.77 (0.40–1.47)
Ptrendg 0.10 0.52 0.12
aDerSimonian–Laird estimators for random effects models were used to com-
bine results from the Nurses’ Health Studies, and the New England Case–Control
study.
bPerhaplotype(VDR)orperphenotype(GC)oddsratios(OR)and95%conﬁdence
intervals (CI) estimated using unconditional logistic regression models adjusted
for matching factors and race.
cP-value for heterogeneity by predicted 25(OH)D levels.
dBelow median predicted 25(OH)D sample size: 496 cases, 842 controls; above
median predicted 25(OH)D sample size: 435 cases, 808 controls.
eGC phenotypes derived from haplotype scores of rs4588 and rs7041 (GC2 hap-
lotype: T-T, GC1s haplotype: G-G, and GC1f haplotype: G-T); in subset of NECC
genotyped on the iCOGS array (34) phenotypes were derived from rs2282679
and rs7041 (GC2 haplotype: C-T, GC1s haplotype: A-G, and GC1f haplotype: A-
T); below median predicted 25(OH)D sample size: 1,084 cases, 1,487 controls;
above median predicted 25(OH)D sample size: 854 cases, 1,334 controls.
fP<0.05 for test for heterogeneity between the Nurses’ Health Studies, and the
New England Case–Control study estimates.
g25(OH)D binding afﬁnity constants (Ka 10
 10 M) assigned to GC phenotypes
for trend test: GC2–GC2, 3.6; GC2–GC1s, 4.8; GC1s–GC1s, 6.0; GC2–GC1f, 7 .4;
GC1s–GC1f, 8.6; GC1f–GC1f, 11.2 (56).
population could not only be used to validate our results,but also
determine the most biologically relevant vitamin D forms [e.g.,
25(OH)D or 1,25(OH)D] to detect differences in genetic associa-
tionswithovariancancerrisk.Additionally,althoughthepredicted
25(OH)DscorehasbeenvalidatedinNHS/NHSII,wewereunable
to assess the performance of the score among NECC participants
due to the absence of measured 25(OH)D levels. While the geo-
graphic distribution of NHS/NHSII participants differs from that
of NECC, many NHS/NHSII women reside in the Northeast and
are of a similar age distribution, which may improve the general-
izability of the score. Finally, our sample size was not sufﬁcient to
assess genetic associations by histologic subtypes.
In summary,we observed heterogeneity in genetic associations
with ovarian cancer risk by predicted 25(OH)D status that was
limited to variation at the 30 end of the VDR gene. Our results
indicate that genetic associations may be missed if 25(OH)D sta-
tus is not considered, potentially contributing to inconsistency
in the literature. Larger studies assessing heterogeneity in ovar-
ian cancer risk by vitamin D status associated with VDR variants
are required to validate our results. If resources are available, use
of plasma 25(OH)D levels instead of predicted 25(OH)D scores
may provide additional information on whether genetic variants
are likely to inﬂuence risk over a particular threshold or range of
25(OH)D. Moreover, functional studies assessing the inﬂuence of
the VDR 30 end variants on expression and activity of VDR and
neighboring genes in ovarian tissue may shed light on the degree
of involvement of the vitamin D pathway compared to alternate
pathways that may involve other genes in the region.
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